To prospectively compare the performance of model-based and model-free dynamic contrast-enhanced (DCE) pharmacokinetic parameters in monitoring breast cancers' early response to neoadjuvant chemotherapy
Sixty patients, with 61 pathology-proven breast cancers, were examined using DCE magnetic resonance imaging before, after the first cycle, and after full cycles of NACT. Both model-based (Ktrans
and others) and model-free parameters, mainly time-intensity curve (TIC), were measured. According to Miller-Payne grading, patients were divided into response and nonresponse group. Mann-Whitney U
test, Fisher exact test, multivariate logistic regression, and receiver operating characteristic curve were used in analysis.
After the first cycle, among all the parameters, Ktrans
and TIC were strongly associated with tumors' early response. There was no significant difference between the areas under receiver operating characteristic curve of Ktrans
and TIC (0.768, 0.852, respectively).
Model-based and model-free DCE
parameters, especially Ktrans
and TIC, have similar performance in predicting the efficacy of NACT for breast cancers.